Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 6,616

Document Document Title
WO/2013/096771A1
Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagon...  
WO/2013/092856A1
The present invention relates to a process for manufacturing a benzoxazinone of formula (I), by reacting a nitro compound of formula (II)with a reducing agent to obtain an amino compound of formula (III), and then reacting the amino comp...  
WO/2013/092859A1
The present invention relates to a process for manufacturing 4-substituted amino- benzoxazinones of formula (I), by reacting a NH-benzoxazinone of formula (II) with a compound of formula (III); wherein the variables are defined according...  
WO/2013/096226A1
Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating...  
WO/2013/086415A1
Provided herein is technology relating to antimicrobial compounds and particularly, but not exclusively, to analogs of rifalazil having increased inhibition of RNA polymerase and decreased induction of human cy-tochrome P450. The compoun...  
WO/2013/085285A1
The present invention relates to a compound having hole conduction properties represented by the following formula 1, to a use thereof as a co-absorbent, and to a solar cell including the compound.  
WO/2013/083556A1
The present invention relates to novel 5-(3-aminophenyl)-5-alkyl-5,6-dihydro- 2H-[1,4]oxazin-3-amine derivatives as inhibitors of beta-secretase, also known as beta- site amyloid cleaving enzyme, BACE, BACE 1, Asp2, or memapsin2. The inv...  
WO/2013/005168A3
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Me...  
WO/2013/056428A1
The present invention relates to a benzoxazine intermediate and a preparation method thereof. The structural formula of the benzoxazine intermediate is shown by formula (1). R1 in formula represents O, C=O, S, SO2, alicyclic hydrocarbon ...  
WO/2013/054291A1
The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereo...  
WO/2013/050270A1
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calc...  
WO/2013/006098A3
The invention relates to sterically hindered phenols, and specifically to terpenophenols, and more precisely, to functional derivatives of isobornylphenol. The group of compounds is represented by formula (I):  
WO/2013/050721A1
The present invention relates to a series of molecules derived from 2,3-diaminopropionic acid (DAP), comprising or not comprising an 8-hydroxyquinoline (8-HQ) motif, and to the use of said molecules for trapping an alpha-oxoaldehyde resu...  
WO/2013/045410A1
Novel spirobifluorene compounds for light emitting devices where an SBF or Open SBF unit is substituted by a nitrogen atom, which is part of a ring system comprising two aromatic or heteroaromatic rings.  
WO/2013/049719A1
The invention relates to the compound 5-(4-isopropylsulfonylphenyl) -3-[3-[4-[(3R)-morpholin-3-yl]phenyl]isoxazol-5-yl]pyrazine- 2-amine and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of ATR kinase.  
WO/2013/049250A1
The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the...  
WO/2013/045411A1
Novel spirobifluorene compounds for light emitting devices where the spirobifluorene ring system comprises at least one acridine-type substituent.  
WO/2013/039185A1
A benzoxazine compound represented by formula (1) (in which X represents a group represented by formula (A-1), formula (A-2), or formula (A-3); R1 through R25 each independently represent a hydrogen atom, a C1-6 alkyl group, a C1-6 alkyl...  
WO/2013/037960A1
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for ...  
WO/2013/033955A1
Provided are a benzoxazine monomer comprising benzocyclobutenyl functional group, synthetic method therefor and use thereof. The benzoxazine monomer comprising benzocyclobutene monomer may be synthesized via two routes: 1. subjecting ami...  
WO/2013/033245A1
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...  
WO/2013/022595A1
The present disclosure provides a method for producing a benzoxazine compound by reacting a phenolic compound with an aldehyde compound and an amine compound in the presence of a solvent system containing a apolar solvent and a polar apr...  
WO/2012/104865A8
The present invention discloses a compound of formula [I] and a process for preparation thereof. The compound exhibits insect repellent properties. The invention also discloses pharmaceutical composition comprising the said compound. For...  
WO/2010/133724A3
The invention relates to halogenated derivatives of 2H-1,4-benzoxazin-3(4H)-one with C-2 alkyl chains or N-4 acyl residues. The invention belongs to the field of chemical compounds that can be used for agricultural pest control. The inve...  
WO/2013/007371A2
The present invention refers to a method for the kinetic resolution of a chiral primary or secondary amine by treating the amine with a chiral, hydroxamic acid derived reagent of the formula (I). These chiral reagents are particularly us...  
WO/2013/000651A1
Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R2', R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositi...  
WO/2012/110833A3
The present invention relates to fluorescence lifetime modulators, conjugates comprising fluorescence lifetime modulators moieties and methods of making them. The present invention further relates to the use of the fluorescence lifetime ...  
WO/2012/168265A1
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, halogen, cyano, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or C(O)NH2, or is phenyl optionally subs...  
WO/2012/160392A1
The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined in the specification. T...  
WO/2012/156284A1
The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds ...  
WO/2012/128582A3
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. ...  
WO/2012/154204A1
Antibacterial compounds of Formula I are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administrat...  
WO/2012/154760A1
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...  
WO/2012/146692A1
The invention provides a salt, preferably in crystalline form, of (2R,3S)-2-[(R)-1-(3,5-Bis- trifluoromethylphenyl)ethoxy]-3-(4-fluorophenyl)morpholine (BFM2) with a Ο,Ο'-substituted tartaric acid derivative. Furthermore, a composition...  
WO/2012/094622A3
Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize aryl alcohol derivatives as cross-coupling partners. Embodiments of the invention include methods for the amination of aryl sul...  
WO/2012/139993A1
The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therape...  
WO/2012/140061A1
The present invention relates to methods for the preparation of a compound having the formula (X). Individual reaction steps as welt as intermediates are additionally claimed.  
WO/2012/136655A1
The present invention relates to compounds useful in the treatment of amyloid diseases, such as Alzheimer's disease. Further, the compounds are useful for imaging amyloid deposits.  
WO/2012/126922A1
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cyclo...  
WO/2012/031298A3
Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-ne...  
WO/2012/104263A3
The present invention relates to 1,4 Oxazines of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active com...  
WO/2012/127385A1
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) recept...  
WO/2012/128582A2
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. ...  
WO/2012/127388A1
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) recepto...  
WO/2012/124719A1
A compound having a benzoxazinone ring and an aromatic ring that is bound directly to the benzoxazinone ring and also having a mesogenic core substituted by a substituent having a polymerizable functional group. The compound has excellen...  
WO/2012/124775A1
The present invention provides a nitrogen-containing saturated heterocyclic compound that is useful as a renin inhibitor/antagonist. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, R1...  
WO/2012/120476A1
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) recept...  
WO/2012/120423A1
The present invention relates to a compound of formula (I) below: or a pharmaceutically acceptable salt thereof, for the use thereof in the prevention or treatment of cancers.  
WO/2012/119927A1
The invention relates to a method for producing primary amines comprising at least one functional group of formula (-CH2-NH2), by alcohol amination of educts which comprise at least one functional group of formula (–CH2-OH), using ammo...  
WO/2012/090177A3
Compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. M...  

Matches 351 - 400 out of 6,616